TY - JOUR
T1 - Screening for chronic obstructive pulmonary disease using spirometry
T2 - Summary of the evidence for the U.S. preventive services task force
AU - Lin, Kenneth
AU - Watkins, Bradley
AU - Johnson, Tamara
AU - Rodriguez, Joy Anne
AU - Barton, Mary B.
PY - 2008/4/1
Y1 - 2008/4/1
N2 - Background: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. Fewer than half of the estimated 24 million Americans with airflow obstruction have received a COPD diagnosis, and diagnosis often occurs in advanced stages of the disease. Purpose: To summarize the evidence on screening for COPD using spirometry for the U.S. Preventive Services Task Force (USPSTF). Data Sources: English-language articles identified in PubMed and the Cochrane Library through January 2007, recent systematic reviews, expert suggestions, and reference lists of retrieved articles. Study Selection: Explicit inclusion and exclusion criteria were used for each of the 8 key questions on benefits and harms of screening. Eligible study types varied by question. Data Extraction: Studies were reviewed, abstracted, and rated for quality by using predefined USPSTF criteria. Data Synthesis: Pharmacologic treatments for COPD reduce acute exacerbations in patients with severe disease. However, severe COPD is uncommon in the general U.S. population. Spirometry has not been shown to independently increase smoking cessation rates. Potential harms from screening include false-positive results and adverse effects from subsequent unnecessary therapy. Data on the prevalence of airflow obstruction in the U.S. population were used to calculate projected outcomes from screening groups defined by age and smoking status. Limitation: No studies provide direct evidence on health outcomes associated with screening for COPD. Conclusion: Screening for COPD using spirometry is likely to identify a predominance of patients with mild to moderate airflow obstruction who would not experience additional health benefits if labeled as having COPD. Hundreds of patients would need to undergo spirometry to defer a single exacerbation.
AB - Background: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. Fewer than half of the estimated 24 million Americans with airflow obstruction have received a COPD diagnosis, and diagnosis often occurs in advanced stages of the disease. Purpose: To summarize the evidence on screening for COPD using spirometry for the U.S. Preventive Services Task Force (USPSTF). Data Sources: English-language articles identified in PubMed and the Cochrane Library through January 2007, recent systematic reviews, expert suggestions, and reference lists of retrieved articles. Study Selection: Explicit inclusion and exclusion criteria were used for each of the 8 key questions on benefits and harms of screening. Eligible study types varied by question. Data Extraction: Studies were reviewed, abstracted, and rated for quality by using predefined USPSTF criteria. Data Synthesis: Pharmacologic treatments for COPD reduce acute exacerbations in patients with severe disease. However, severe COPD is uncommon in the general U.S. population. Spirometry has not been shown to independently increase smoking cessation rates. Potential harms from screening include false-positive results and adverse effects from subsequent unnecessary therapy. Data on the prevalence of airflow obstruction in the U.S. population were used to calculate projected outcomes from screening groups defined by age and smoking status. Limitation: No studies provide direct evidence on health outcomes associated with screening for COPD. Conclusion: Screening for COPD using spirometry is likely to identify a predominance of patients with mild to moderate airflow obstruction who would not experience additional health benefits if labeled as having COPD. Hundreds of patients would need to undergo spirometry to defer a single exacerbation.
UR - http://www.scopus.com/inward/record.url?scp=42249096140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42249096140&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-148-7-200804010-00213
DO - 10.7326/0003-4819-148-7-200804010-00213
M3 - Review article
C2 - 18316746
AN - SCOPUS:42249096140
SN - 0003-4819
VL - 148
SP - 535
EP - 543
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 7
ER -